Bladder Cancer

About Bladder Cancer Clinical Trials (Click to Open)

Join Clinical Trials for Bladder Cancer

Clinical Trials for Bladder CancerGeneral Purpose:

It is estimated that over 73,000 cases of bladder cancer will be diagnosed in the United States in 2012. If you have been diagnosed with bladder cancer, you may be interested in participating in a clinical trial in order to receive a cutting edge medication or surgical procedure, or simply participate in hopes that the information learned from the trial – regardless of what it is investigating – might one day be of benefit to future bladder cancer patients.

Fortunately, there are clinical trials for bladder cancer investigating a variety of topics pertaining to the condition, including new treatment options. Some research is working to better understand the genetic characteristics of bladder cancer and identify if certain DNA changes can help to predict the prognosis of patients with bladder cancer.

Other research is evaluating new testing methods for bladder cancer screening, such as urine tests that identify substances that might indicate an individual has bladder cancer.

People who are diagnosed with bladder cancer have an increased risk of their cancer recurring, as well as developing cancer in other parts of their urinary system. In turn, researchers are currently evaluating if certain vitamins and dietary supplements, as well as chemotherapy drugs, can reduce the risk of the cancer returning.

What Will Clinical Trials for Bladder Cancer Be Like?

When participating in a bladder cancer clinical trial, there are a few basic tests and procedures you may receive; however, the ultimate design of the particular study will determine which specific procedures you will undergo. The following tests and procedures are often used during clinical trials for bladder cancer:

  • Physical exam
  • Urine test to determine the presence of sugar, protein, red blood cells, and white blood cells
  • Blood tests
  • Examination of urine under a microscope to check for abnormal cells
  • A procedure known as cystoscopy, which involves inserting a thin, lighted tube with a tiny camera on the end into the bladder to view the organ and/or to remove a tissue sample.
  • Imaging procedures such as x-rays of the kidneys, ureters, and bladder. These x-rays will often involve injection of a non-toxic dye into the vein, which then moves through the kidneys, ureters, and bladder allowing doctors to identify any possible blockages.
  • Computed tomography scan (CT scan, or “CAT scan”), which takes detailed pictures of areas inside the body.
  • Biopsy
  • Quality of life assessments that evaluate how much of an impact your cancer is having on your daily life

Typical Bladder Cancer Clinical Trial Protocol:

Currently, research related to bladder cancer spans a wide range of topics. Specific Clinical Trials for Bladder Cancerexamples might include the following:

  • A study designed to see injection of a modified virus into the bladder can selectively infect and kill bladder cancer cells, leaving healthy tissue untouched.
  • A clinical trial evaluating the effectiveness of chemotherapy combined with a new drug that prevents the growth of blood vessels that allow tumors to grow.
  • Studies designed to see if supplementation with the mineral selenium can help prevent the recurrence of bladder cancer.
  • Studies that involve providing tissue samples through biopsies, so that genetic testing can be done to help better understand common mutations seen in bladder cancer cells.
  • A trial designed to evaluate the association between the diabetes drug pioglitazone and the risk of developing bladder cancer.

A brief word about randomized trials and placebos:

Many clinical trials involve the comparison of an investigational treatment to an existing or “standard” treatment for the cancer. The exact therapy (i.e., investigational or standard) that each patient receives in such a trial is usually determined through a process known as randomization, in which patients are randomly assigned to receive either the investigational treatment or the standard treatment.

Sometimes, a trial will investigate the use of a standard treatment plus a new drug compared to standard treatment plus a placebo. Placebos are inactive or sham treatments that are identical to the active treatment; however they have no therapeutic value.

Clinical Trials for Bladder CancerThe purpose for using a placebo is to be certain that any adverse effects that occur during the clinical trial are actually the result of the investigational treatment and not some other factor. In these types of trials, all patients receive the standard treatment, while those randomized to the investigational treatment also receive the investigational drug.

In rare instances where no standard therapy exists, or when a new drug is being evaluated for the first time in a specific cancer, the investigational treatment might be compared to a placebo alone. In these types of trials, those patients who are randomized to the placebo group do not receive an active treatment.

This is rarely done in clinical trials for bladder cancer, however, and is only done when it is necessary from a scientific standpoint, is ethically appropriate, and when patients have been adequately informed that they may receive the placebo.

Therefore, it is important to understand that if you are interested in participating in a trial that involves the use of a placebo alone (i.e., without standard treatment because none exists), you may end up receiving the placebo rather than the active treatment being investigated. Often times, patients are reluctant to join a trial that involves the use of a placebo for fear that they will not receive an active treatment.

While that may occasionally be the case, individuals who receive placebos are necessary to clinical research because their responses during the study allow researchers to better measure the effects of the active treatment being studied, and help the researchers observe what would have happened without the active treatment.

It is also important to understand that it is not appropriate for an individual to participate in a placebo-controlled trial when there is a widely available and highly effective standard treatment already in existence for their cancer.

Trial Eligibility and Medical Information Needed:

The type of clinical trial you may be eligible for often depends on whether you have been newly diagnosed with cancer, or if you have already received treatment. In addition, eligibility may also be determined based on the stage of your cancer.

Therefore, it is important to know the exact details of your cancer diagnosis when searching for clinical trials, i.e. clinical trials for bladder cancer, of potential interest. Specific details you will want to make note of and have on hand include the following:

  • The official name of your cancer (e.g., transitional cell carcinoma of the bladder)
  • Knowledge of where your cancer first started. For example, if you have bladder cancer that spread to the kidneys, it is still considered bladder cancer.
  • Know your cancer’s cell type. This information can be located in your pathology report.
  • Know the size of your tumor.
  • Know the locations of any and all metastases that have been diagnosed.
  • Know the stage of your cancer. This describes the extent of your cancer, and whether it has spread to other sites in the body. Each individual cancer has its own staging system, so be sure to know and understand the staging system specific to bladder cancer.
  • Know your prior history of cancer (e.g., if you were diagnosed with lung cancer prior to your diagnosis of bladder cancer, be sure to have all the details pertaining to that diagnosis as well).
  • Know your current performance status, which is an assessment performed by your doctor to determine how well you are able to perform normal activities of daily living. Two common scales used to evaluate the performance of cancer patients include the Karnofsky Performance Scale (KPS) and the ECOG scale.
  • Know what treatments you have already received for your cancer. Examples might include chemotherapy, radiation therapy, immunotherapy, and/or surgery.
  • Know your bone marrow function test results, including your white blood cell count, platelet count, and hemoglobin/hematocrit.
  • Know your liver function test results, including bilirubin and transaminases.
  • Know your kidney function (also referred to as renal function) test result, which includes serum creatinine.

Suggested Search Terms:

“bladder cancer chemotherapy,” “bladder cancer surgery,” “metastatic bladder cancer,” “bladder cancer smoking,” “bladder cancer recurrence,” “neoadjuvant chemotherapy bladder cancer,” “bladder cancer genetics,” and “bladder cancer symptoms.”

Current Search Term:

“Bladder Cancer”

Add Comments or Questions



Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer


Condition:   Bladder Cancer
Interventions:   Drug: Durvalumab;   Drug: Tremelimumab;   Radiation: Radiation Therapy
Sponsors:   Terence Friedlander, MD;   MedImmune LLC
Withdrawn


Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer


Condition:   Bladder Cancer
Interventions:   Drug: Celecoxib;   Drug: Gemcitabine;   Drug: Cisplatin
Sponsor:   Baylor College of Medicine
Recruiting


Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer


Condition:   Bladder Cancer
Interventions:   Drug: Pembrolizumab;   Drug: Cisplatin;   Radiation: Radiotherapy
Sponsors:   Australian and New Zealand Urogenital and Prostate Cancer Trials Group;   Peter MacCallum Cancer Centre, Australia
Recruiting


Enzalutamide for Bladder Cancer Chemoprevention


Condition:   Bladder Cancer
Intervention:   Drug: Enzalutamide
Sponsors:   University of Rochester;   Astellas Pharma Inc
Recruiting


A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting


Condition:   Bladder Cancer
Interventions:   Drug: Hexaminolevulinate hydrochloride;   Device: KARL STORZ D-Light C PDD Flexible Videoscope System
Sponsors:   Photocure;   KARL STORZ Endoscopy-America, Inc.
Completed


VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer


Condition:   Bladder Cancer
Intervention:   Drug: VPM1002BC
Sponsor:   Swiss Group for Clinical Cancer Research
Recruiting


Exploratory Investigation of Advanced PET/MRI Metrics for Bladder Cancer Characterization


Condition:   Bladder Cancer
Intervention:   Procedure: PET/MRI
Sponsors:   New York University School of Medicine;   Society of Abdominal Radiology
Completed


Investigating Bladder Chemotherapy Instead of Surgery for Low Risk Bladder Cancer


Condition:   Bladder Cancer
Interventions:   Drug: Mitomycin C;   Procedure: Surgical Management
Sponsors:   Institute of Cancer Research, United Kingdom;   National Institute for Health Research, United Kingdom
Recruiting


Biomarker Identification for Bladder Cancer Patients


Condition:   Bladder Cancer
Intervention:   Procedure: Sample Collection
Sponsor:   Ohio State University Comprehensive Cancer Center
Recruiting


Single Subject Neratinib in Bladder Cancer (NRR)


Condition:   Bladder Cancer
Intervention:   Drug: Neratinib
Sponsor:   UNC Lineberger Comprehensive Cancer Center
No longer available


An Educational Intervention for Patients With Bladder Cancer


Condition:   Bladder Cancer
Interventions:   Behavioral: Education Intervention;   Behavioral: Nutrition Intervention
Sponsor:   Icahn School of Medicine at Mount Sinai
Completed


Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer


Condition:   Relapsed Bladder Cancer
Intervention:   Drug: TORISEL
Sponsors:   Institut Bergonié;   Wyeth is now a wholly owned subsidiary of Pfizer
Completed


BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients


Condition:   Bladder Cancer
Interventions:   Biological: MAGE-A3 ASCI;   Biological: BCG
Sponsors:   Patrice Jichlinski;   Ludwig Center for Cancer Research of Lausanne;   GlaxoSmithKline
Completed


Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer


Condition:   Bladder Cancer
Interventions:   Drug: gemcitabine plus cisplatin;   Drug: E7389 in combination with gemcitabine plus cisplatin
Sponsors:   Eisai Inc.;   PharmaBio Development Inc.
Completed


Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer


Condition:   Bladder Cancer
Interventions:   Drug: cisplatin;   Drug: fluorouracil;   Drug: mitomycin C
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   NRG Oncology
Recruiting


3 Tesla MRI in Patients With Bladder Cancer


Condition:   Bladder Cancer
Interventions:   Procedure: Specimen Ultra-High field MRI;   Drug: chemotherapy;   Procedure: Cystectomy and Lymphadenectomy
Sponsor:   Ohio State University Comprehensive Cancer Center
Recruiting


Molecular Analysis Of Bladder Cancer


Conditions:   Bladder Cancer;   Bladder Neoplasms
Intervention:  
Sponsor:   Lahey Clinic
Active, not recruiting


Follow-Up of Bladder Cancer Patients From the New England Study of Environment and Health


Condition:   Bladder Cancer
Intervention:  
Sponsor:   National Cancer Institute (NCI)
Completed


Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)


Condition:   Bladder Cancer
Interventions:   Drug: Apaziquone;   Drug: Placebo;   Procedure: TURBT
Sponsor:   Spectrum Pharmaceuticals, Inc
Completed


Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)


Condition:   Bladder Cancer
Interventions:   Drug: Apaziquone;   Drug: Placebo;   Procedure: TURBT
Sponsor:   Spectrum Pharmaceuticals, Inc
Completed


Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer


Condition:   Bladder Cancer
Interventions:   Drug: Erlotinib;   Procedure: Radical Cystectomy
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   OSI Pharmaceuticals;   National Cancer Institute (NCI)
Completed


The New England Bladder Cancer Study


Condition:   Bladder Cancer
Intervention:  
Sponsor:   National Cancer Institute (NCI)
Completed


NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers.


Condition:   Bladder Cancer
Intervention:   Device: Nuclear Matrix Protein 22 Urine sample kit
Sponsor:   Lawson Health Research Institute
Completed


Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer


Condition:   Bladder Cancer
Interventions:   Drug: cisplatin;   Drug: fluorouracil;   Drug: paclitaxel;   Radiation: radiation therapy;   Drug: Gemcitabine;   Procedure: Radical cystectomy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   NRG Oncology
Active, not recruiting


4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer


Condition:   Bladder Cancer
Interventions:   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: methotrexate;   Drug: vinblastine
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   NCIC Clinical Trials Group;   University of Southern California
Terminated

Refine Your Search Advanced Search